Buyout expands Walgreens specialty-pharmacy patient base by 500,000
Even while Walgreens, the biggest chain pharmacy by number of stores, is duking out dispensing-reimbursement issues with the PBM Express Scripts (which is in the process of acquiring Medco, one of the other leading PBMs), it continues to build its specialty-pharmacy foundation. The latest is the acquisition of BioScrips (Elmsford, NY) which has a national network of specialty pharmacies at 30 locations, a home-infusion practice and a central fill facility, mostly for HIV, oncology and transplant patients. Bioscrips has also provided prescription dispensing services for Drugstore.com, which Walgreens acquired in June 2011. Purchase prices was $285 million (including future performance incentives). The pharmacy locations, home health and infusion services will continue as Bioscrips entities.
“Together, BioScrip's clinically focused community specialty pharmacies and access to additional limited distribution drug therapies, and Walgreens existing nationwide network of retail and health system pharmacies create a strong network of support for our core drugstore business to provide specialty pharmacy solutions to our patients,” said Walgreens President and CEO Greg Wasson. “Many of our patients will benefit from expanded access to new and limited distribution drugs for chronic conditions such as HIV, cancer and organ transplant. This acquisition also significantly expands our nationwide reach to an additional half-million patients with chronic and complex health conditions who have strong clinical relationships with their current BioScrip pharmacy.”
Retail pharmacies in general, and Walgreens in particular, are striving to move their business model more into a component of overall healthcare, especially for chronically ill—which is something that many pharma companies are eyeing as well.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.